



(11) **EP 3 911 372 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
04.01.2023 Bulletin 2023/01

(45) Date of publication and mention
of the grant of the patent:
30.11.2022 Bulletin 2022/48

(21) Application number: **20700204.9**

(22) Date of filing: **09.01.2020**

(51) International Patent Classification (IPC):
A61K 51/04 ^(2006.01) **A61K 101/02** ^(2006.01)
C07B 59/00 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 51/0406; C07B 59/001

(86) International application number:
PCT/EP2020/050406

(87) International publication number:
WO 2020/148154 (23.07.2020 Gazette 2020/30)

(54) **COMPOUND TARGETING NOREPINEPHRINE TRANSPORTER**
AUF NOREPINEPHRINTRANSPORTER ABZIELENDE VERBINDUNG
COMPOSÉ CIBLANT LE TRANSPORTEUR DE NORÉPINÉPHRINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **17.01.2019 EP 19152274**

(43) Date of publication of application:
24.11.2021 Bulletin 2021/47

(73) Proprietor: **Beijing Lado Technology Co. Ltd.**
Beijing, 100082 (CN)

(72) Inventors:
• **DECKER, Michael**
97074 Würzburg (DE)
• **HIGUCHI, Takahiro**
97080 Würzburg (DE)
• **CHEN, Xinyu**
97078 Würzburg (DE)

(74) Representative: **Vos, Derk**
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München (DE)

(56) References cited:
WO-A2-2008/083056 WO-A2-2013/036869

- **GANESAN VAIDYANATHAN ET AL: "Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG", NUCLEAR MEDICINE AND BIOLOGY., vol. 42, no. 8, 1 August 2015 (2015-08-01), pages 673-684, XP055604085, US ISSN: 0969-8051, DOI: 10.1016/j.nucmedbio.2015.04.005 cited in the application**
- **R. A. WERNER ET AL: "Retention Kinetics of the 18F-Labeled Sympathetic Nerve PET Tracer LMI1195: Comparison with 11C-Hydroxyephedrine and 123I-MIBG", THE JOURNAL OF NUCLEAR MEDICINE, vol. 56, no. 9, 16 July 2015 (2015-07-16), pages 1429-1433, XP055382282, US ISSN: 0161-5505, DOI: 10.2967/jnumed.115.158493 cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).